Skip to main content
Log in

FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

FosB is a member of the AP-1 family of transcription factors which represent important regulators of cell proliferation and differentiation. Based on prior results which indicated a role of FosB in breast cancer, we studied FosB protein and mRNA expression by immunohistochemistry and, partly, in situ hybridization in 68 mammary carcinomas and normal breast tissues. We found strong nuclear FosB immunoreactivity in epithelial cells of normal lobules and ducts, whereas carcinomas frequently showed loss of FosB expression (n = 8) or weak immunostaining (n = 24). Reduced FosB protein expression in tumors correlated with high grading (p = 0.005), negative estrogen and progesterone receptor status (p < 0.001), and strong HER2/neu expression (p = 0.025). Comparison with expression of seven cell-cycle regulators revealed an association of low/absent FosB staining with p16MTS1 overexpression (p = 0.005). RT-PCR showed expression of full-length FosB and the smaller splice variant FosB2 in most carcinomas and cell lines with and without FosB protein expression, indicating that both proteins are differentially regulated mainly at a post-transcriptional level. By sequence analysis of the coding region in four cell lines and 17 carcinomas we detected a mutation in HBL-100 cells. Our results indicate that high FosB expression might be necessary for normal proliferation and differentiation of mammary epithelial cells, and reduced FosB protein levels might be involved in dedifferentiation during breast tumorigenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991

    Google Scholar 

  2. Karin M, Liu Z-G, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997

    Google Scholar 

  3. Ransone LJ, Visvader J, Lamph WW, Sassone-Corsi P, Verma IM: Fos and Jun interaction: the role of the leucine zipper. Int J Cancer 4: 10-21, 1989

    Google Scholar 

  4. Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001

    Google Scholar 

  5. Van Dam H, Castellazzi M: Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene 20: 2453-2464, 2001

    Google Scholar 

  6. Ransone LJ, Verma IM: Nuclear proto-oncogenes Fos and Jun. Ann Rev Cell Biol 6: 539-557, 1990

    Google Scholar 

  7. Lee W, Mitchell P, Tjian R: Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752, 1987

    Google Scholar 

  8. Ryseck R-P, Bravo R: c-Jun, JunB, and JunD differ in their binding affinities to AP-1 and CRE consensus sequences: effect of Fos proteins. Oncogene 6: 533-542, 1991

    Google Scholar 

  9. Finzer P, Soto U, Delius H, Patzelt A, Coy JF, Poustka A, zur Hausen H, Rösl F: Differential transcriptional regulation of the monocyte chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV18 positive cells: the role of chromatin structure and AP-1 composition. Oncogene 19: 3235-3244, 2000

    Google Scholar 

  10. Krosl J, Sauvageau G: AP-1 complex is effector of Hoxinduced cellular proliferation and transformation. Oncogene 19: 5134-5141, 2000

    Google Scholar 

  11. Mechta F, Lallemand D, Pfarr CM, Yaniv M: Transformation by ras modifies AP-1 composition and activity. Oncogene 14: 837-847, 1997

    Google Scholar 

  12. Pospelova TV, Medvedev AV, Kukushkin AN, Svetlikova SB, van der Eb AJ, Dorsman JC, Pospelov VA: E1A+cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. Gene Expr 8: 19-32, 1999

    Google Scholar 

  13. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ: c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070, 1999

    Google Scholar 

  14. Soto U, Denk C, Finzer P, Hutter KJ, zur Hausen H, Rösl F: Genetic complementation to non-tumorigenicity in cervicalcarcinoma cells correlates with alterations in AP-1 composition. Int J Cancer 86: 811-817, 2000

    Google Scholar 

  15. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P: Neoplastic transformation of rat thyroid cells requires the JunB and Fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310-5321, 1997

    Google Scholar 

  16. Chung JY, Huang C, Meng X, Dong Z, Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 59: 4610-4617, 1999

    Google Scholar 

  17. Darne C, Martinez A, Lallemand D, Morel L, Jean C, Saru JP, Schmid HP, Manin M: Down-regulation of AP-1 activities after polarization of vas deferens epithelial cells correlates with androgen-induced gene expression. J Steroid Biochem Mol Biol 72: 103-113, 2000

    Google Scholar 

  18. Ng DC, Shafaee S, Lee D, Bikle DD: Requirement of an AP-1 site in the calcium response region of the involucrin promoter. J Biol Chem 275: 24080-24088, 2000

    Google Scholar 

  19. Zerial M, Toschi L, Ryseck R-P, Schuermann M, Müller R, Bravo R: The product of a novel growth factor activated gene, FosB, interacts with Jun proteins enhancing their DNA binding activity. EMBO J 8: 805-813, 1989

    Google Scholar 

  20. Mumberg D, Lucibello FC, Schuermann M, Müller R: Alternative splicing of FosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Gene Dev 5: 1212-1223, 1991

    Google Scholar 

  21. Metz R, Kouzarides T, Bravo R: A C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is able to interact with the TATA binding protein, is required for altered cell growth. EMBO J 13: 3832-3842, 1994

    Google Scholar 

  22. Angel P, Szabowski A, Schorpp-Kistner M: Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 20: 2413-2423, 2001

    Google Scholar 

  23. Welter JF, Eckert RL: Differential expression of the Fos and Jun family members c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD during human epidermal keratinocyte differentiation. Oncogene 11: 2681-2687, 1995

    Google Scholar 

  24. Brown JR, Ye H, Bronson RT, Dikkes P, Greenberg ME: A defect in nurturing in mice lacking the immediate early gene FosB. Cell 86: 297-309, 1996

    Google Scholar 

  25. Gruda MC, van Amsterdam J, Rizzo CA, Durham SK, Lira S, Bravo R: Expression of FosB during mouse development: normal development of FosB knockout mice. Oncogene 12: 2177-2185, 1996

    Google Scholar 

  26. Jochum W, Passegué E, Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412, 2001

    Google Scholar 

  27. Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of FosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558, 1999

    Google Scholar 

  28. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Löning T: Expression of cell cycle regulatory proteins Rb, p16/MTS1, p27/Kip1, p21/Waf1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 87: 468-472, 2000

    Google Scholar 

  29. Milde-Langosch K, Bamberger A-M, Rieck G, Kelp B, Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70, 2001

    Google Scholar 

  30. Milde-Langosch K, Riethdorf S, Kraus-Pöppinghaus A, Riethdorf L, Löning T: Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 439: 55-61, 2001

    Google Scholar 

  31. Remmele W, Stegner H-E: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987

    Google Scholar 

  32. Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM, Löning T: Expression of Rb2/p130 in breast and endometrial cancer: correlations with steroid hormone receptor status and Rb expression. Br J Cancer 85: 552-556, 2001

    Google Scholar 

  33. Riethdorf L, Riethdorf S, Gützlaff K, Prall F, Löning T: Differential expression of the monocyte chemoattractant protein-1 in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 149: 1469-1475, 1996

    Google Scholar 

  34. Schlott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, Droese M: Point mutations and nucleotide insertions in the mdm2 zinc finger structure of human tumours. J Pathol 182: 54-61, 1997

    Google Scholar 

  35. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histological parameters. Int J Cancer 79: 71-75, 1998

    Google Scholar 

  36. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, Wallwiener D, Sinn H-P: Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668, 1998

    Google Scholar 

  37. Passegue E, Wagner EF: JunB suppresses cell proliferation by transcriptional activation of p16 (INK4a) expression. EMBO J 19: 2969-2979, 2000

    Google Scholar 

  38. Rinehart-Kim J, Johnston M, Birrer M, Bos T: Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer 88: 180-190, 2000

    Google Scholar 

  39. Heximer SP, Cristillo AD, Russell L, Forsdyke DR: Sequence analysis and expression in cultured lymphocytes of the human FOSB gene (GOS3). DNA Cell Biol 15: 1025-1038, 1996

    Google Scholar 

  40. Carillo S, Pariat M, Steff A-M, Roux P, Etienne-Julan M, Lorca T, Piechaczyk M: Differential sensitivity of Fos and Jun family members to calpains. Oncogene 9: 1679-1689, 1994

    Google Scholar 

  41. Salvat C, Aquaviva C, Jariel-Encontre I, Ferrara P, Pariat M, Stef AM, Carillo S, Piechaczyk M: Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep 26: 45-51, 1999

    Google Scholar 

  42. Lucibello FC, Slater EP, Jooss KU, Beato M, Müller R: Mutual transrepression of Fos and the glucocorticoid receptor: involvement of a functional domain in Fos which is absent in FosB. EMBO J 9: 2827-2834, 1990

    Google Scholar 

  43. Rosen JM, Zahnow C, Kazansky A, Raught B: Composite response elements mediate hormonal and developmental regulation of milk protein gene expression. Biochem Soc Symp 63: 101-113, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milde-Langosch, K., Kappes, H., Riethdorf, S. et al. FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas. Breast Cancer Res Treat 77, 265–275 (2003). https://doi.org/10.1023/A:1021887100216

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021887100216

Navigation